Medical oncologists provide comprehensive insights on treatment practices for patients with extended-stage small cell lung cancer.
Understanding “Paradigm-Changing” Events in Small Cell Lung Cancer Care
The frontline treatment algorithm in SCLC is poised to look “radically different” in the upcoming years, according to Anne Chiang, MD, PhD.
Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting
Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.
Toripalimab Consolidation Improves Survival in Limited-Stage SCLC
In patients with LS-SCLC who were ineligible for a prophylactic cranial irradiation, toripalimab appeared to decrease the progression of brain metastases.
Considering Dosing and AE Management Strategies With Tarlatamab in SCLC
Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.
Cisplatin/Carboplatin Plus Etoposide Yield Similar Real-World Efficacy in ES-SCLC
Cisplatin/etoposide and carboplatin/etoposide achieved median OS of 8.8 months and 7.8 months, respectively, in those with extensive-stage small cell lung cancer.
I-DXd Shows “Impressive” Responses in Extensive-Stage SCLC
Data from the IDeate-Lung01 trial support the potential role that ifinatamab deruxtecan may play in the management of extensive-stage small cell lung cancer.